Cubist Systematic Strategies LLC raised its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 1,304.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 84,202 shares of the company’s stock after purchasing an additional 78,207 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.14% of Protagonist Therapeutics worth $2,918,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of PTGX. Kynam Capital Management LP increased its stake in Protagonist Therapeutics by 10.2% in the fourth quarter. Kynam Capital Management LP now owns 2,004,875 shares of the company’s stock valued at $45,972,000 after purchasing an additional 186,218 shares during the period. Superstring Capital Management LP acquired a new position in shares of Protagonist Therapeutics during the fourth quarter worth about $8,694,000. ADAR1 Capital Management LLC acquired a new position in shares of Protagonist Therapeutics during the fourth quarter worth about $4,606,000. Birchview Capital LP increased its stake in shares of Protagonist Therapeutics by 26.3% during the fourth quarter. Birchview Capital LP now owns 48,000 shares of the company’s stock worth $1,101,000 after acquiring an additional 10,000 shares during the period. Finally, Opaleye Management Inc. acquired a new position in shares of Protagonist Therapeutics during the fourth quarter worth about $2,584,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Protagonist Therapeutics
In other Protagonist Therapeutics news, Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the transaction, the director now owns 12,000 shares of the company’s stock, valued at approximately $540,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director William D. Waddill sold 8,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the transaction, the director now owns 12,000 shares of the company’s stock, valued at approximately $540,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the transaction, the chief financial officer now directly owns 34,960 shares in the company, valued at approximately $1,555,370.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,203 shares of company stock valued at $1,311,891. Company insiders own 5.40% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Analysis on PTGX
Protagonist Therapeutics Stock Performance
Protagonist Therapeutics stock opened at $44.56 on Monday. The firm’s 50-day moving average is $41.76 and its 200-day moving average is $34.26. Protagonist Therapeutics, Inc. has a 1 year low of $13.72 and a 1 year high of $48.00. The company has a market cap of $2.62 billion, a P/E ratio of 18.26 and a beta of 2.17.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.50) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.50). The firm had revenue of $4.17 million during the quarter, compared to analyst estimates of $40.00 million. As a group, sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.31 earnings per share for the current year.
Protagonist Therapeutics Profile
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Read More
- Five stocks we like better than Protagonist Therapeutics
- Stock Market Upgrades: What Are They?
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Why is the Ex-Dividend Date Significant to Investors?
- MarketBeat Week in Review – 9/23 – 9/27
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.